


IN THIS SUPPLEMENT
PRIMARY THERAPY OF EARLY BREAST CANCER
15TH ST.GALLEN INTERNATIONAL BREAST CANCER CONFERENCE
VIENNA, AUSTRIA, 15-18 MARCH 2017

THE BREAST

An Associate Journal of the Australasian Society for Breast Disease
Affiliated with the European Society of Breast Cancer Specialists
Official Journal of the Breast Centres Network



THE BREAST

PRIMARY THERAPY OF EARLY BREAST CANCER

Evidence, Controversies, Consensus

**15th St.Gallen International Breast Cancer Conference
Vienna/Austria, 15–18 March 2017**

Conference Chairpersons

Giuseppe Curigliano, Milano/Italy

Michael Gnant, Vienna/Austria

Martine Piccart, Brussels/Belgium

Meredith Regan, Boston/Md, USA

Hans-Jörg Senn, St.Gallen/Switzerland

Beat Thürlimann, St.Gallen/Switzerland

Eric Winer, Boston/Md, USA

THE BREAST

Editor-in-Chief

Fatima Cardoso, Champalimaud Cancer Centre, Lisbon, Portugal

Co-Editors

Nehmat Houssami, University of Sydney, Sydney, Australia

Giuseppe Curigiano, European Institute of Oncology, Milan, Italy

Epidemiology and prevention:

Imaging, screening and early diagnosis:

Familial and Hereditary Breast Cancer:

Pathology:

Surgery and gynecology:

Medical oncology:

Radiation Oncology:

Translational Research:

Psycho-oncology and Quality of Life:

Survivorship:

Advocacy:

Specialty Editor

E. Negri, Milan, Italy

N. Houssami, Sydney, Australia

S. Delaloge, Paris, France

G. Pruneri, Milan, Italy

M.J. Cardoso, Lisbon, Portugal

A. Rody, Luebeck, Germany

E. Senkus, Gdansk, Poland

P. Francis, Melbourne, Australia

P. Poortmans, Nijmegen, The Netherlands

S. Di Cosimo, Milan, Italy

M. Solbjør, Trondheim, Norway

K. Ruddy, Rochester, USA

Australasian Society for Breast Disease Representative

R. Stuart-Harris Canberra, Australia

J. Harvey Perth, Australia

EUSOMA – European Society of Breast Cancer Specialists Representative

C. Markopoulos Athens, Greece

St Gallen Oncology Conferences Representatives

H.J. Senn St Gallen, Switzerland

B. Thürlimann St Gallen, Switzerland

Breast Centres Network Representative

C. Tinterri Milan, Italy

International Advisory Board

B. Anderson Seattle, USA

F. André Villejuif, France

B. Arun Houston, Texas, USA

H.A. Azim Marseille, France

G.S. Bhattacharyya West Bengal, India

G. de Bock Groningen, The Netherlands

J. Bogaert Brussels, Belgium

E. Brain Saint-Cloud, France

M. Brennan Sydney, Australia

R.E. Coleman Sheffield, UK

J. Cortes Barcelona, Spain

T. Cufer Ljubljana, Slovenia

S. Delalogue Villejuif, France

R. Dent Prato, Italy

J. M. Dixon Edinburgh, Scotland

S. Duffy London, UK

L.E.M. Duijm Nijmegen, Netherlands

N. El Saghir Beirut, Lebanon

W. Gatzemeier Milan, Italy

P. Ganz Los Angeles, USA

J. Gligorov Paris, France

S. Hurvitz Santa Monica, USA

G. Jerusalem Liège, Belgium

B. Kaufman Ramat Gan, Israel

H. de Koning Eindhoven,
The Netherlands

S. Kyriakides Nicosia, Cyprus

A. Di Leo Prato, Italy

B. Linderholm Gothenburg, Sweden

L. Lusa Ljubljana, Slovenia

B. Mann Parkville, Australia

S. Nakamura Tokyo, Japan

S. Ohno Fukuoka, Japan

M. Paesmans Brussels, Belgium

O. Pagani Lugano, Switzerland

A. Partridge Boston, USA

F.A. Peccatori Milan, Italy

F. Penault-Llorca Clermont-Ferrand, France

G. Pravettoni Milan, Italy

K. Pritchard Toronto, Canada

M.M. Regan Boston, Massachusetts, USA

I. Rubio Barcelona, Spain

V. Sacchini New York, NY, USA

K. Sandelin Stockholm, Sweden

F. Sardanelli Milan, Italy

G. Schwartzmann Porto Alegre, Brazil

V. Semiglazov St. Petersburg, Russia

L. Solin Philadelphia, USA

V. Speirs Leeds, UK

E. Tagliabue Milan, Italy

A. Tagliafico Genova, Italy

D.A. Vorobiof Johannesburg, S.A.

M.G. Wallis Cambridge, UK

N. Williams London, UK

Y. Yarden Tel Aviv, Israel

S. Zackrisson Malmö, Sweden

J. Žgajnar Ljubljana, Slovenia



www.elsevier.com/brst

An Associate Journal of the Australasian Society for Breast Disease: www.asbd.org.au

Affiliated with the European Society of Breast Cancer Specialists: www.eusoma.org

Official Journal of Breast Centres Network: www.BreastCentresNetwork.org

Amsterdam . Boston . London . New York . Oxford . Paris . Philadelphia .

San Diego . St Louis

Contents

Scientific program – overview

Speakers' Abstracts

Wednesday, 15 March 2017

Opening address by the St.Gallen 2017	
Award Winner (Prof. Martine Piccart-Gebhart, Belgium)	S1
Award Lecture by the ESO Umberto Veronesi Memorial	
Award Winner (Prof. Giuseppe Curigliano, Italy)	S1
Session 1: News since St.Gallen 2015: De-escalating and escalating treatment according to stage and breast cancer subtype	S2
Session 2: Biology of breast cancer I: Overcoming resistance to treatment in early breast cancer	S3

Thursday, 16 March 2017

Session 3: Biology of breast cancer II: Intratumoral heterogeneity and therapeutic implications	S5
Session 4: Genetics and prevention of invasive breast cancer	S6
Special lecture I	S8
Session 5: Research translation into clinic: Targetable pathways on the horizon	S9
Session 6: Pathology for risk stratification and treatment tailoring	S10

Friday, 17 March 2017

Session 7: Surgery of early breast cancer: De-escalation and escalation	S12
Session 8: Radiotherapy in early breast cancer 2017: De-escalation and escalation	S15
Special lecture II	S17
Session 9: Primary and adjuvant systemic therapy of early breast cancer I	S18
Session 10: Primary and adjuvant systemic therapy of early breast cancer II	S20

Poster Abstracts I

Thursday, 16 March 2017

Adjuvant systemic therapy	S22
Biology/Pathology/Basic Research	S28
Epidemiology/ Prevention/Diagnosis	S50
Locally advanced and metastatic disease	S64
Radiotherapy/IORT	S70

Poster Abstracts II

Friday, 17 March 2017

Neoadjuvant (pre-operative) therapy	S78
Health politics/Guidelines	S84
Predictive and prognostic factors	S87
Surgery/Sentinels/DCIS	S110
Other	S128

Author Index	S133
---------------------	------

P251**Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study**

S. Stemmer^{1,2*}, M. Steiner³, S. Rizel¹, D. Geffen⁴, B. Nisenbaum⁵, T. Peretz⁶, K. Isaacs⁷, O. Rosengarten⁸, G. Fried⁹, C. Svedman¹⁰, N. Ben-Baruch¹¹. ¹Davidoff Center, Rabin Medical Center, Petah Tikva, Israel, ²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Lin Medical Center, Haifa, Israel, ⁴Dept. of Oncology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel, ⁵Oncology Dept., Meir Medical Center, Kfar Saba, Israel, ⁶Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ⁷Oncology Dept., Ha'emek Medical Center, Afula, Israel, ⁸Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel, ⁹Oncology Dept., Rambam Health Care Campus, Haifa, Israel, ¹⁰Genomic Health Inc., Redwood City, CA, ¹¹Oncology Dept., Kaplan Medical Center, Rehovot, Israel

Aims: Recent outcome data including those from the prospective TAILORx trial strongly confirmed the role of the Recurrence Score® (RS) in node negative (N0) estrogen receptor (ER)+ human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The prospective WSG PlanB study showed excellent outcomes in high-risk N0 and node-positive (N+) patients with RS ≤ 11 and no adjuvant chemotherapy. RS testing is increasingly being used in N+ ER+ HER2-negative breast cancer. Our aim was to evaluate treatments/clinical outcomes in N+ BC patients tested through Clalit Health Services (CHS).

Methods: This prospectively-designed cohort study included patients with micrometastases or 1–3 positive axillary nodes who were RS-tested from 1/2006 (CHS approval of the test) through 12/2011. Medical records were reviewed to verify treatments/recurrences/survival.

Results: The analysis included 709 patients with a median follow-up of 5.9 years. Median age was 62 years, 53.9% had grade 2 tumors, 69.8% had tumors ≤ 2 cm, 84.5% had invasive ductal carcinoma, 42.0% were N1mi, whereas 37.2%, 15.5%, and 5.2% had 1, 2, and 3 positive nodes, respectively; 53.4% had RS < 18, 36.4% RS 18–30, and 10.2% RS ≥ 31. Overall, 26.9% received adjuvant chemotherapy: 7.1%, 39.5%, and 86.1% of those with RS < 18, 18–30, and ≥ 31, respectively. The 5-year Kaplan-Meier (KM) estimates for distant recurrence were 3.2%, 6.3%, and 16.9% for patients with RS < 18, 18–30 and ≥ 31, respectively; the corresponding 5-year estimates for breast cancer death were 0.5%, 2.9%, and 5.7%. In RS < 18 patients, 5-year distant recurrence rates were 1.2% for N1mi, 4.4% for 1 positive node, and 5.4% for 2–3 positive nodes. As patients were not randomized to treatment and treatment decision is heavily influenced by RS, analysis of 5-year distant recurrence by chemotherapy use was exploratory. In RS < 18 patients, recurrence rate was 7.7% in chemotherapy-treated (n = 27) compared to 2.9% in chemotherapy-untreated patients (n = 352); P = 0.245. In RS 18–30 patients, however, recurrence rate in chemotherapy-treated patients (n = 102) was significantly lower than in untreated patients (n = 156) (1.0% vs 9.7% P = 0.019).

Conclusions: Chemotherapy use was aligned with the RS results. The findings support using endocrine therapy alone in ER+ HER2-negative breast cancer patients with micrometastases/1–3 positive nodes and RS < 18.

Disclosure of Interest: Salomon M. Stemmer reports consulting for Novartis; receiving grant funding from Teva; receiving travel expenses from Genomic Health, Inc; and conducting research funded by Teva. Noa Ben-Baruch reports receiving honoraria from Teva, and serving on the speaker's bureau of Genomic Health. All other authors report no conflict of interest.

P252**On consolidated predictive model of the natural history of breast cancer considering primary tumour and distant metastases growth**

E. Tyuryumina*, A. Neznanov. *International Laboratory for Intelligent Systems and Structural Analysis (ISSA), National Research University Higher School of Economics, Moscow, Russian Federation*

Aims: The research aim is to improve predicting accuracy of breast cancer (BC) progression using an original mathematical model referred to CoMPaS and corresponding software. We are interested in: (1) modelling the whole natural history of the primary tumor (PT) and the distant metastases (MTS); (2) developing adequate and precise CoMPaS which reflects relations between PT and MTS; (3) analysing the CoMPaS scope of application; (4) implementing the model as a software tool.

Methods: The CoMPaS is based on exponential tumor growth model and consists of a system of determinate nonlinear and linear equations; corresponds to TNM classification. It allows to calculate different growth periods of the PT and MTS: (1) “non-visible period” for PT; (2) “non-visible period” for MTS; (3) “visible period” for MTS. The CoMPaS is validated on clinical data of 10-years and 15-years survival depending on the tumor stage and diameter of the PT (1. Engel J. et al. Eur J. Cancer. 2003; 39(12): 1794–1806; 2. Engel J. et al. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55(5): 1186–1195; 3. Engel J. et al. Cancer Metastasis. 2012; 31(1–2): 235–246). The new predictive tool: (1) is a solid foundation to develop future studies of BC models; (2) does not require any expensive diagnostic tests; (3) is the first predictor which makes forecast using only current patient data, the others are based on the additional statistical data.

Results: The CoMPaS model and predictive software: (a) fit to clinical trials data; (b) detect different growth periods of the PT and MTS; (c) make forecast of the period of MTS appearance; (d) have higher average prediction accuracy than the other tools; (e) can improve forecasts on survival of BC and facilitate optimization of diagnostic tests.

Conclusions: The following are calculated by CoMPaS: the number of doublings for «non-visible» and «visible» growth period of MTS; tumor volume doubling time (days) for «non-visible» and «visible» growth period of MTS.

The CoMPaS enables, for the first time, to predict “whole natural history” of the PT and MTS growth on each stage (pT1, pT2, pT3, pT4) relying only on PT sizes.

Summarizing: (a) CoMPaS describes correctly PT growth of IA, IIA, IIB, IIB (T1–4N0M0) stages without metastases in lymph nodes (N0); (b) facilitates the understanding of the appearance period and inception of MTS.

Disclosure of Interest: No significant relationships.

P253**Pathological complete response after neoadjuvant therapy in patients undergoing breast conservative therapy: an experience from tertiary care hospital**

I. Ul Islam Nasir*, M. Salim, O. Shakeel, A. Iqbal Khan. *Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan*

Aim: Our aim was to identify the factors responsible for pathological complete response after neoadjuvant therapy.

Methods: All the patients who presented to our hospital from Jan 2006 to Dec 2013 with breast cancer and underwent breast conservative therapy (BCT) were analyzed. We included all the patients who received neoadjuvant therapy followed by BCT and excluded all those in whom upfront surgery and mastectomy was performed. On follow-up examinations, occurrence of loco regional and/or distant disease was considered as recurrence. The SPSS version 20 was utilized for all statistical analyses. Kaplan-Meier curve was employed to estimate the overall and disease-free survival. Multivariate cox proportional hazard model was used for the